ReviewHeliyon2024
Blood hypercoagulability and thrombosis mechanisms in cancer patients -A brief review.
Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Machine learning-based prediction of intraoperative blood transfusion in major surgery: exploiting clinical variables and systemic inflammatory indices.Annals of medicine · 2026Article
- Cancer-associated left ventricular thrombus with preserved ejection fraction: A multicenter descriptive study.American heart journal plus : cardiology research and practice · 2026Article
- Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System.International journal of clinical pharmacy · 2026Article
- Non-linear association between body mass index and port-related thrombosis in breast cancer patients: a retrospective cohort study.BMC cancer · 2026Article
- Subacute normotensive cardiac tamponade as the initial presentation of metastatic lung adenocarcinoma: a case report.Journal of medical case reports · 2026Article
- Cardiac valve mass revealed by venous and arterial embolism: case report and review of the literature.European heart journal. Case reports · 2026Article
- Breast Cancer-Associated Venous Thromboembolism: Risk Factors, Mechanisms, and Clinical Management.Cancers · 2026Review
- Integrated serum proteomics and metabolomics reveal an INR-associated multi-omics signature in hepatocellular carcinoma.Clinical proteomics · 2026Article
- The role of hematological biomarkers as diagnostic tool in pre-cancerous patients.Discover oncology · 2026Review
- Catheter-Based Valvular and Structural Interventions in Cancer Patients.Current cardiology reports · 2026Review
- Preoperative Fibrinogen as a Biomarker Associated With Lymphovascular Space Invasion in Endometrial Carcinoma: A Cross-Sectional Study.Journal of family & reproductive health · 2026Article
- Cancer-Associated Thrombosis in Patients Treated with Immune Checkpoint Inhibitors.International journal of molecular sciences · 2026Review
- Circulating tumor cells and circulating tumor microemboli: role in venous thromboembolism in oncologic patients.Bioscience reports · 2026Review
- Clinical features and prognosis of patients with malignant tumors complicated by cerebral infarction.American journal of cancer research · 2026Article
- Risk stratification of in-hospital venous thromboembolism for urological cancers: a multicenter retrospective study.Therapeutic advances in medical oncology · 2026Article
- CLEC3B (tetranectin) expression is associated with vascular localization and tumor aggressiveness in breast cancer.International journal of medical sciences · 2026Article
- Research Advances on Targets and Mechanisms in Cancers Complicated by Cardiovascular Diseases.OncoTargets and therapy · 2026Review
- Immune checkpoint inhibitors combined with chemotherapy enhance coagulation activation and elevate venous thromboembolism risk in non-small cell lung cancer.American journal of cancer research · 2026Article
- Clinical phenotype identification based on inflammation-nutrition-coagulation biomarkers in advanced non-small cell lung cancer.Frontiers in nutrition · 2026Article
- Status quo of hypercoagulation as a prognostic indicator following neoadjuvant immunochemotherapy in locally advanced gastric cancer.World journal of gastrointestinal oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with malignant tumors are prone to present hypercoagulability of blood and form thrombosis, and its pathogenesis is complex involving various factors from clinical and histopathological to genetic influences. Current studies on the potential mechanism of blood hypercoagulability in patients with malignant tumors focus on the following aspects but are not limited: (1) tumor cells release coagulant-promoting substances, (2) tumor cells interact with the fibrinolytic system, (3) tumor cell-mediated platelet activation, (4) tumor-associated complement activation, and (5) genetic factors and clinical factors. Especially, the pathogenesis of blood hypercoagulability is in-depth analyzed covering tumor cells' release of procoagulant substances, the interplay of cancer cells and fibrinolytic system, platelet activation mediated by cancer cells, cancer-associated complement activation, and the action of genetic and clinical factors. We review the pathogenesis of blood hypercoagulability in patients with malignant tumors, which will assist in the research and development of new drugs and providing theoretical support for the formulation of the best treatment plan for patients, to prolong the survival of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.